Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.

被引：0
|
作者：
Castagnola, C [1 ]
Alessandrino, EP [1 ]
Pagnucco, G [1 ]
Bernasconi, P [1 ]
Lunghi, M [1 ]
Colombo, A [1 ]
Brusamolino, E [1 ]
Bonfichi, M [1 ]
Corso, A [1 ]
Lazzarino, M [1 ]
Bernasconi, C [1 ]
机构：
[1] Univ Pavia, IRCCS, Policlin San Matteo, Div Hematol, I-27100 Pavia, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4627
引用
收藏
页码：210B / 210B
页数：1
相关论文
共 50 条
  • [31] The value of oral cytarabine ocfosfate and etoposide in the treatment of patients with refractory AML and AML in elderly patients
    Horikoshi, A
    Takei, K
    Nakagawa, Y
    Hosokawa, Y
    Sawada, S
    EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 76 - 76
  • [32] MEC (MITOXANTRONE, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE) - AN EFFECTIVE INDUCTION REGIMEN FOR PREVIOUSLY UNTREATED ACUTE NONLYMPHOCYTIC LEUKEMIA
    VISANI, G
    PETTI, MC
    CENACCHI, A
    MANFROI, S
    TOSI, P
    SPADEA, A
    LATAGLIATA, R
    AMADORI, S
    MANDELLI, F
    TURA, S
    LEUKEMIA & LYMPHOMA, 1995, 19 (5-6) : 447 - 451
  • [33] A multicentre trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory AML or CML in blast crisis - Interim results.
    Hoechsmann, B
    Doehner, H
    Ganser, A
    Heil, G
    Denzlinger, C
    Einsele, H
    Duerk, H
    Raghavachar, A
    Hoelzer, D
    Bergmann, L
    BLOOD, 2001, 98 (11) : 213B - 213B
  • [34] Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
    Scappini, Barbara
    Gianfaldoni, Giacomo
    Caracciolo, Francesco
    Mannelli, Francesco
    Biagiotti, Caterina
    Romani, Claudio
    Pogliani, Enrico M.
    Simonetti, Federico
    Borin, Lorenza
    Fanci, Rosa
    Cutini, Ilaria
    Longo, Giovanni
    Susini, Maria Chiara
    Angelucci, Emanuele
    Bosi, Alberto
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1047 - 1051
  • [35] Phase I/II study of escalating doses of mitoxantrone in a single injection combined with timed sequential therapy with cytarabine and etoposide in patients with refractory or relapsed acute myeloid leukemia (AML).
    Thomas, X
    Cambier, N
    Taksin, AL
    Reman, O
    Vekhoff, A
    Cordonnier, C
    Leblond, V
    Soler-Michel, P
    Ecstein-Fraïssé, E
    Archimbaud, E
    BLOOD, 1999, 94 (10) : 238B - 238B
  • [36] The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients
    Horikoshi, Akira
    Takei, Kazuhiro
    Hosokawa, Yoshifumi
    Sawada, Shigemasa
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 87 (02) : 118 - 125
  • [37] Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma
    Emmanouilides, C
    Lill, M
    Telatar, M
    Rosenfelt, F
    Grody, W
    Territo, M
    Rosen, P
    CLINICAL LYMPHOMA, 2002, 3 (02): : 111 - 116
  • [38] The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients
    Akira Horikoshi
    Kazuhiro Takei
    Yoshifumi Hosokawa
    Shigemasa Sawada
    International Journal of Hematology, 2008, 87 : 118 - 125
  • [39] A PEDIATRIC-ONCOLOGY-GROUP (POG) PHASE-II TRIAL OF MITOXANTRONE, ETOPOSIDE AND CYCLOSPORINE A (MEC) THERAPY FOR RELAPSED AND REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)
    DAHL, G
    DUNUSSI, K
    MOGUL, M
    BROPHY, N
    LOWE, K
    GRIER, H
    SIKIC, B
    WEINSTEIN, H
    ARCECI, R
    BLOOD, 1993, 82 (10) : A195 - A195
  • [40] Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia -: An Eastern Cooperative Oncology Group Pilot Study
    Tallman, MS
    Lee, S
    Sikic, BI
    Paietta, E
    Wiernik, PH
    Bennett, JM
    Rowe, JM
    CANCER, 1999, 85 (02) : 358 - 367
12345